This is not only superfluous given that medicines produced in this way are exclusively intended for the market of selected LDCs, which is at the core of the regulation, but also conflicts with the rules laid down in Regulation (EC) No 726/2004, Article 58 of which is echoed in paragraph 2.
This is not only superfluous given that medicines produced in this way are exclusively intended for the market of selected LDCs, which is at the core of the regulation, but also conflicts with the rules laid down in Regulation (EC) No 726/2004, Article 58 of which is echoed in paragraph 2.